DE69837931D1 - Jnk3 modulatoren und verfahren zu ihrer verwendung - Google Patents

Jnk3 modulatoren und verfahren zu ihrer verwendung

Info

Publication number
DE69837931D1
DE69837931D1 DE69837931T DE69837931T DE69837931D1 DE 69837931 D1 DE69837931 D1 DE 69837931D1 DE 69837931 T DE69837931 T DE 69837931T DE 69837931 T DE69837931 T DE 69837931T DE 69837931 D1 DE69837931 D1 DE 69837931D1
Authority
DE
Germany
Prior art keywords
jnk3
modulators
jnk3 modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69837931T
Other languages
English (en)
Other versions
DE69837931T2 (de
Inventor
Roger J Davis
Richard A Flavell
Pasko Rakic
Alan J Whitmarsh
Chia-Yin Kuan
Derek Di Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts UMass
Original Assignee
University of Massachusetts UMass
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Massachusetts UMass filed Critical University of Massachusetts UMass
Publication of DE69837931D1 publication Critical patent/DE69837931D1/de
Application granted granted Critical
Publication of DE69837931T2 publication Critical patent/DE69837931T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69837931T 1997-10-03 1998-10-05 Jnk3 modulatoren und verfahren zu ihrer verwendung Expired - Lifetime DE69837931T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6099597P 1997-10-03 1997-10-03
US60995P 1997-10-03
PCT/US1998/020904 WO1999018193A1 (en) 1997-10-03 1998-10-05 Jnk3 modulators and methods of use

Publications (2)

Publication Number Publication Date
DE69837931D1 true DE69837931D1 (de) 2007-07-26
DE69837931T2 DE69837931T2 (de) 2008-02-21

Family

ID=22033003

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69841792T Expired - Lifetime DE69841792D1 (de) 1997-10-03 1998-10-05 JNK3-Modulatoren und Verwendungsverfahren dafür
DE69837931T Expired - Lifetime DE69837931T2 (de) 1997-10-03 1998-10-05 Jnk3 modulatoren und verfahren zu ihrer verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69841792T Expired - Lifetime DE69841792D1 (de) 1997-10-03 1998-10-05 JNK3-Modulatoren und Verwendungsverfahren dafür

Country Status (8)

Country Link
US (3) US6943000B2 (de)
EP (1) EP1027429B1 (de)
JP (2) JP2001519146A (de)
AU (1) AU756401B2 (de)
CA (1) CA2302874C (de)
DE (2) DE69841792D1 (de)
HK (1) HK1031128A1 (de)
WO (1) WO1999018193A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6943000B2 (en) * 1997-10-03 2005-09-13 University Of Massachusetts JNK3 modulators and methods of use
US7383135B1 (en) * 1998-05-04 2008-06-03 Vertex Pharmaceuticals Incorporated Methods of designing inhibitors for JNK kinases
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6653064B1 (en) 1999-09-23 2003-11-25 Boehringer Ingelheim International Gmbh Method for identifying compounds useful in the therapy of bone disorders
EP1087230A1 (de) * 1999-09-24 2001-03-28 Boehringer Ingelheim International GmbH Verfahren zum Nachweis von Verbindungen nützlich in Therapie von Knochenfehlern
DE10036501B4 (de) * 2000-07-25 2004-08-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur Messung der JNK/SAPKs-Aktivität mittels der Bestimmung der Phosphorylierung von Transkriptionsfaktoren
DE10037759A1 (de) * 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
US7049080B2 (en) * 2000-08-11 2006-05-23 Joachim Kramer Process for detecting serine/threonine kinase activity
EP1860199B1 (de) 2001-01-12 2014-03-05 Exelixis, Inc. Modulierte Signalisierung von Insulinrezeptoren
CA2474689A1 (en) * 2002-01-31 2003-08-07 Celestar Lexico-Sciences, Inc. Drugs ameliorating circadian rhythum disorder
WO2008151323A1 (en) * 2007-06-08 2008-12-11 University Of Massachusetts Mixed lineage kinases and metabolic disorders
WO2009009045A2 (en) * 2007-07-10 2009-01-15 The Scripps Research Institute Escape libraries of target polypeptides
WO2010151638A1 (en) 2009-06-25 2010-12-29 Medical College Of Georgia Research Institute, Inc. Jnk inhibitors for use in treating spinal muscular atrophy
WO2018152223A1 (en) * 2017-02-15 2018-08-23 University Of Massachusetts Methods of treating angiogenesis-related disorders using jnk3 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593844A (en) * 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5534426A (en) 1993-07-19 1996-07-09 The Regents Of The University Of California Oncoprotein protein kinase
US6514745B1 (en) 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US6001584A (en) 1993-07-19 1999-12-14 The Regents Of The University Of California Oncoprotein protein kinase
US5736381A (en) 1995-05-19 1998-04-07 Davis; Roger J. Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
ATE395419T1 (de) 1997-07-03 2008-05-15 Asahi Kasei Pharma Corp Neue mapk kinase
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6943000B2 (en) * 1997-10-03 2005-09-13 University Of Massachusetts JNK3 modulators and methods of use

Also Published As

Publication number Publication date
AU1186099A (en) 1999-04-27
EP1027429A4 (de) 2002-11-20
HK1031128A1 (en) 2001-06-01
US20060035303A1 (en) 2006-02-16
EP1027429A1 (de) 2000-08-16
JP2010233570A (ja) 2010-10-21
WO1999018193A1 (en) 1999-04-15
CA2302874C (en) 2011-07-12
US6943000B2 (en) 2005-09-13
AU756401B2 (en) 2003-01-09
US20120240247A1 (en) 2012-09-20
DE69837931T2 (de) 2008-02-21
CA2302874A1 (en) 1999-04-15
US20030023990A1 (en) 2003-01-30
JP2001519146A (ja) 2001-10-23
DE69841792D1 (de) 2010-09-09
EP1027429B1 (de) 2007-06-13

Similar Documents

Publication Publication Date Title
DE69721223D1 (de) Membranaffinitätssystem und verfahren zu dessen verwendung
DE69519809D1 (de) Bandulierungssystem und verfahren zu dessen verwendung
DE69521333D1 (de) Reinigungsmittel und verfahren zu dessen verwendung
DE69608025D1 (de) Müllsammelbehälter und Verfahren zu seiner Verwendung
DE69535554D1 (de) Lumineszente lanthanidenchelate und verfahren zu ihrer verwendung
DE69825674D1 (de) Rückbeleuchteter Fotodetektor und Methode zu dessen Herstellung
DE69839615D1 (de) Photonischer-Kristall-Wellenleiter und Verfahren seiner Verwendung
DE69834401D1 (de) Businterfacesystem und verfahren
DE69830222D1 (de) Reformer und Methode zu dessen Betreiben
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
DE69837931D1 (de) Jnk3 modulatoren und verfahren zu ihrer verwendung
DE69635929D1 (de) Klebstoffzusammensetzungen und methoden zu ihrer verwendung
DE69611189D1 (de) Planarer Wellenleiter und Verfahren zu seiner Herstellung
DE69812585D1 (de) Fluidmischer und verfahren für seine verwendung
DE69720807D1 (de) Verändliche graphik und verfahren zu ihrer herstellung und verwendung
DE69907526T2 (de) Einsatzdruckzerstäuberdüse und Verfahren zu ihrer Verwendung
DE69927535D1 (de) Sprühdüse und Verfahren zu ihrer Verwendung
ATE188338T1 (de) Synergistische herbizide zusammensetzung und verfahren zu ihre verwendung
DE69811220D1 (de) Zusammensetzungen zum konservieren von lebenden biologischen materialien und verfahren zu ihrer verwendung
DE69707642D1 (de) Keramischer zünder und verfahren zu seiner verwendung
DE69714990D1 (de) Modifizierter polysiloxan-katalysator und verfahren zu seiner verwendung
DE59804730D1 (de) Siebelement und Verfahren zu siener Herstellung
DE69836105D1 (de) Nagel und Verfahren zu seiner Herstellung
DE60032381D1 (de) Polierzusammensetzung und verfahren zu ihrer verwendung
EE9900365A (et) Elektersides kasutatav seade ja meetod

Legal Events

Date Code Title Description
8364 No opposition during term of opposition